Arcturus Therapeutics unveiled new dietary intake and biochemical data from its ARCT-810 mRNA study in ornithine transcarbamylase deficiency. The SSIEM 2026 update covered adolescent and adult patients, adding to evidence for the therapy’s potential.
published
Arcturus Therapeutics unveiled new dietary intake and biochemical data from its ARCT-810 mRNA study in ornithine transcarbamylase deficiency. The SSIEM 2026 update covered adolescent and adult patients, adding to evidence for the therapy’s potential.
Latest documented BWB result
$TSLA · $SPY market result
Exit $TSLA PDS with a .60 profit per contract - was willing to hold if $SPY closed under the SMA 50 but not with a close above it
Historical results are not a promise of future performance. Trading involves substantial risk.This public post is a timestamped information archive, not personalized financial advice. Alerts can change as markets move. Join Billy's private group for the complete daily stream and follow-through.